Funding sources: G.M.H. is a Senior Principal Research Fellow of the National Health and Medical Research Council of Australia (no. 630434).
The neurobiological basis of cognitive impairment in Parkinson's disease
Article first published online: 22 APR 2014
© 2014 International Parkinson and Movement Disorder Society
Special Issue: Cognition and Movement Disorders
Volume 29, Issue 5, pages 634–650, 15 April 2014
How to Cite
Halliday, G. M., Leverenz, J. B., Schneider, J. S. and Adler, C. H. (2014), The neurobiological basis of cognitive impairment in Parkinson's disease. Mov. Disord., 29: 634–650. doi: 10.1002/mds.25857
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 22 APR 2014
- Article first published online: 22 APR 2014
- Manuscript Accepted: 13 FEB 2014
- Manuscript Revised: 8 FEB 2014
- Manuscript Received: 17 DEC 2013
- Parkinson's disease dementia;
- genetic risk;
- preclinical models
The recent formalization of clinical criteria for Parkinson's disease with dementia (PDD) codifies many studies on this topic, including those assessing biological correlates. These studies show that the emergence of PDD occurs on the background of severe dopamine deficits with, the main pathological drivers of cognitive decline being a synergistic effect between alpha-synuclein and Alzheimer's disease pathology. The presence of these pathologies correlates with a marked loss of limbic and cortically projecting dopamine, noradrenaline, serotonin, and acetylcholine neurons, although the exact timing of these relationships remains to be determined. Genetic factors, such as triplications in the α-synuclein gene, lead to a clear increased risk of PDD, whereas others, such as parkin mutations, are associated with a reduced risk of PDD. The very recent formalization of clinical criteria for PD with mild cognitive impairment (PD-MCI) allows only speculation on its biological and genetic bases. Critical assessment of animal models shows that chronic low-dose MPTP treatment in primates recapitulates PD-MCI over time, enhancing the current biological concept of PD-MCI as having enhanced dopamine deficiency in frontostriatal pathways as well as involvement of other neurotransmitter systems. Data from other animal models support multiple transmitter involvement in cognitive impairment in PD. Whereas dopamine dysfunction has been highlighted because of its obvious role in PD, the role of the other neurotransmitter systems, neurodegenerative pathologies, and genetic factors in PD-MCI remains to be fully elucidated. © 2014 International Parkinson and Movement Disorder Society